SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients.

Among heart transplant (HT) recipients, a reduced immunological response to SARS-CoV-2 vaccination has been reported. We aimed to assess the humoral and T-cell response to SARS-CoV-2 vaccination in HT recipients to understand determinants of immunogenicity. HT recipients were prospectively enrolled from January 2021 until March 2022. Anti-SARS-CoV-2-Spike IgG levels were quantified after two and three doses of a SARS-CoV-2 vaccine (BNT162b2, mRNA1273, or AZD1222). Spike-specific T-cell responses were assessed using flow cytometry. Ninety-one patients were included in the study (69% male, median age 55 years, median time from HT to first vaccination 6.1 years). Seroconversion rates were 34% after two and 63% after three doses. Older patient age (

Informations de copyright

Copyright © 2023 Memenga, Kueppers, Borof, Kirchhof, Duengelhoef, Barten, Lütgehetmann, Berisha, Fluschnik, Becher, Kondziella, Bernhardt, Reichenspurner, Blankenberg, Magnussen and Rybczynski.

Déclaration de conflit d'intérêts

SK received scholarship funding from the German Academic Scholarship Foundation and the German Centre for Cardiovascular Research (DZHK) and travel support from the International Society for Heart and Lung Transplantation. PK receives research support for basic, translational, and clinical research projects from the European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation. PK was partially supported by European Union BigData@Heart (grant agreement EU IMI 116074), AFFECT-AF (grant agreement 847770), and MAESTRIA (grant agreement 965286). PK has received honoraria from several pharmaceutical and medical device companies in the past, but not in the last 3 years. PK is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). All outside the submitted work. NF reports grants from Biotronik. All outside the submitted work. PB received funding from the German Research Foundation. All outside the submitted work. AB has received honoraria, consultancy fees and/or research support from Abbott, Abiomed, AstraZeneca, BerlinHeart, Medtronic (unrelated to the submitted work). SB has received speaker fees from Medtronic, Pfizer, Roche, Novartis, SiemensDiagnostics (unrelated to the submitted work). CM receives research funding from the German Center for Cardiovascular Research (DZHK) within the Promotion of women scientists’ program, the Deutsche Stiftung fuer Herzforschung and the Dr. Rolf Schwiete Stiftung and has received Honoraria from AstraZeneca, Novartis, Heinen & Loewenstein, Boehringer Ingelheim/Lilly, Bayer, Pfizer, Sanofi, Aventis, Apontis, Abbott (unrelated to the submitted work). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.